Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

Catalyst Pharmaceuticals (CPRX), a commercial-stage biopharmaceutical company, is highlighted by Zacks Investment Research as a top long-term value stock, holding a Zacks #2 (Buy) Rank and an 'A' VGM and Value Style Score. This assessment is driven by an attractive forward P/E of 9.56 and recent upward revisions to its FY2025 earnings estimates by analysts, with the consensus estimate increasing by $0.10 to $2.25 per share. Zacks' methodology, which combines its proprietary Rank (historically delivering +23.62% annual returns for #1 stocks) with complementary Style Scores, identifies stocks with the highest probability of outperformance when both metrics are strong.

Analysis

Catalyst Pharmaceutical (CPRX) is presented as a compelling investment opportunity, primarily driven by its strong value characteristics and positive earnings momentum according to the Zacks rating framework. The company holds a Zacks Rank of #2 (Buy) and top-tier 'A' ratings for both its Value and overall VGM Style Scores. This assessment is quantitatively supported by an attractive forward P/E ratio of 9.56. Furthermore, the outlook for future earnings appears robust, with four analysts having revised their fiscal 2025 earnings estimates upward over the past 60 days. This collective revision has lifted the Zacks Consensus Estimate by $0.10 to $2.25 per share for that period. The company's operational performance is further underscored by a historical average earnings surprise of +28.2%, indicating a consistent pattern of exceeding market expectations. The combination of these factors—a strong proprietary rank, favorable style scores, attractive valuation metrics, and upward analyst revisions—positions this commercial-stage biopharmaceutical firm as a noteworthy candidate for outperformance.

Key Decisions for Investors

• Given the stock's 'A' Value Score and a forward P/E of 9.56, value-oriented investors should consider CPRX an attractive candidate for their portfolio.
• The positive trend in earnings estimate revisions is a critical driver of the bull case; therefore, investors should monitor for continued upward revisions to the FY2025 consensus estimate as a key performance indicator.
• The combination of a strong Zacks Rank (#2 Buy) and top-tier Style Scores presents a compelling signal, suggesting investors should view the stock's blend of valuation and earnings momentum favorably.